Specialist healthcare company BTG plc (BTG) said, in an update for the year ended 31 March 2013, that the group has delivered a strong financial performance and has achieved its key business objectives for the year.
The company expects annual revenue to be around 230 million pounds, reflecting good performances across the business, in particular from the Specialty Pharmaceuticals and Licensing & Biotechnology business areas.
The company stated that movements since January 2013, when revenue was expected to be around the high end of the previous guidance range of 205 million pounds - 215 million pounds, included increased forecast royalties from Zytiga or abiraterone acetate, for which actual royalties will be known later this month, the agreement of a final sum relating to the discontinued CytoFab programme, favourable exchange rate movements and a strong end to the year from the Specialty Pharmaceuticals business area.
Louise Makin, CEO of BTG, said, "We start the new financial year with confidence and much to look forward to, including the potential approval of PEM, the potential granting of HDEs for our novel pre-loaded bead products and the initiation of additional studies to support the expanded use of the bead products in patients with liver cancer."
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.